[go: up one dir, main page]

WO2005031357A3 - Analyse d'echantillon cellulaire - Google Patents

Analyse d'echantillon cellulaire Download PDF

Info

Publication number
WO2005031357A3
WO2005031357A3 PCT/GB2004/004010 GB2004004010W WO2005031357A3 WO 2005031357 A3 WO2005031357 A3 WO 2005031357A3 GB 2004004010 W GB2004004010 W GB 2004004010W WO 2005031357 A3 WO2005031357 A3 WO 2005031357A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell sample
cells
sample analysis
provides
flow cytometric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/004010
Other languages
English (en)
Other versions
WO2005031357A2 (fr
Inventor
George Janossy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Biomedica PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322382A external-priority patent/GB0322382D0/en
Priority claimed from GB0322384A external-priority patent/GB0322384D0/en
Priority claimed from GB0328310A external-priority patent/GB0328310D0/en
Application filed by UCL Biomedica PLC filed Critical UCL Biomedica PLC
Publication of WO2005031357A2 publication Critical patent/WO2005031357A2/fr
Publication of WO2005031357A3 publication Critical patent/WO2005031357A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1402—Data analysis by thresholding or gating operations performed on the acquired signals or stored data

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de cytométrie en flux permettant d'analyser un échantillon cellulaire par dénombrement des populations de CD4+, CD38+ et CD8+ contenues dans ledit échantillon. Ce procédé est particulièrement utile dans la surveillance de l'infection VIH. L'invention concerne également un procédé servant à regrouper les lymphocytes T CD8+ en lymphocytes CD38+ normaux et lymphocytes CD38++ pathogènes, dans un procédé de cytométrie en flux consistant à identifier une population de monocytes dans un échantillon cellulaire de référence, et à définir une fenêtre d'analyse en fonction de l'expression CD38 de cette population.
PCT/GB2004/004010 2003-09-24 2004-09-21 Analyse d'echantillon cellulaire Ceased WO2005031357A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0322384.9 2003-09-24
GB0322382.3 2003-09-24
GB0322382A GB0322382D0 (en) 2003-09-24 2003-09-24 Cell sample analysis
GB0322384A GB0322384D0 (en) 2003-09-24 2003-09-24 Cell sample analysis
GB0328310.8 2003-12-05
GB0328310A GB0328310D0 (en) 2003-12-05 2003-12-05 Cell sample analysis

Publications (2)

Publication Number Publication Date
WO2005031357A2 WO2005031357A2 (fr) 2005-04-07
WO2005031357A3 true WO2005031357A3 (fr) 2005-08-11

Family

ID=34396794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004010 Ceased WO2005031357A2 (fr) 2003-09-24 2004-09-21 Analyse d'echantillon cellulaire

Country Status (1)

Country Link
WO (1) WO2005031357A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052258A1 (fr) * 2006-10-31 2008-05-08 Inivai Technologies Pty Ltd Système et procédé permettant de traiter des données obtenues par cytométrie de flux
WO2009135271A1 (fr) * 2008-05-08 2009-11-12 Inivai Technologies Pty Ltd Système et procédé de traitement de données de cytométrie en flux
CN113188982B (zh) * 2021-04-30 2022-05-10 天津深析智能科技发展有限公司 淋巴细胞亚群自动分析中有效去除单核细胞干扰的方法
WO2024025967A1 (fr) * 2022-07-28 2024-02-01 Springworks Therapeutics, Inc. Détermination du taux de bcma sur des cellules plasmatiques par cytométrie de flux

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156951A (en) * 1989-07-13 1992-10-20 Becton Dickinson And Company Detecting immunological changes in HIV infected patient samples
US5470701A (en) * 1993-02-24 1995-11-28 The Regents Of The University Of California Method for determining favorable prognosis in an HIV positive subject using HLA-DR+ /CD38- CD8bright cells
US5538856A (en) * 1991-07-05 1996-07-23 The Regents Of The University Of California Screening kit and method for diagnosing chronic immune dysfunction syndrome
WO1999058977A1 (fr) * 1998-05-11 1999-11-18 Miltenyi Biotec Gmbh Methode de selection directe de cellules t antigenes-specifiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156951A (en) * 1989-07-13 1992-10-20 Becton Dickinson And Company Detecting immunological changes in HIV infected patient samples
US5538856A (en) * 1991-07-05 1996-07-23 The Regents Of The University Of California Screening kit and method for diagnosing chronic immune dysfunction syndrome
US5470701A (en) * 1993-02-24 1995-11-28 The Regents Of The University Of California Method for determining favorable prognosis in an HIV positive subject using HLA-DR+ /CD38- CD8bright cells
WO1999058977A1 (fr) * 1998-05-11 1999-11-18 Miltenyi Biotec Gmbh Methode de selection directe de cellules t antigenes-specifiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHUN T.-W. ET AL.: "Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals.", PROC. NATL. ACAD. SCI. USA, vol. 101, no. 8, 24 February 2004 (2004-02-24), pages 2464 - 2469, XP002330022 *
JANOSSY G. ET AL.: "Affordable CD4+-T-cell counting by flow cytometry: CD45 gating for volumetric analysis.", CLIN. DIAGN. LAB. IMMUNOL., vol. 9, no. 5, September 2002 (2002-09-01), pages 1085 - 1094, XP002330021 *
RAMZAOUI S. ET AL.: "During HIV infection, CD4+CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+CD38- T-cells.", CLIN. IMMUNOL. IMMUNOPATHOL., vol. 77, no. 1, October 1995 (1995-10-01), pages 33 - 41, XP004851372 *
TILLING R. ET AL.: "Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.", AIDS, vol. 16, no. 4, 8 March 2002 (2002-03-08), pages 589 - 596, XP002330020 *

Also Published As

Publication number Publication date
WO2005031357A2 (fr) 2005-04-07

Similar Documents

Publication Publication Date Title
EP4546353A3 (fr) Systèmes et procédés d'analyse de populations de cellules mixtes
WO2002082057A3 (fr) Cytometre a focalisation par dedoublement
WO2007131507A3 (fr) Procédés destinés à des analyses de cytométrie de flux de cellules non lysées issues de fluides biologiques
EP1887357A3 (fr) Analyseur et procédé d'analyse
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
WO2004029221A3 (fr) Dispositif microfluidique pour la separation de cellules et utilisations de ce dispositif
AU2002365421A1 (en) Methods and compositions for detecting the activation state of the multiple proteins in single cells
WO2005072399A3 (fr) Cytometre permettant le triage a l'echelle microscopique
BRPI0407299A (pt) Métodos para detectar um analito associado com o hiv, para determinar a relação de células t cd4+ para células t cd8+, e para detectar rna do hiv, em uma amostra de sangue
ATE266204T1 (de) ßFLOW-ZYTOMETRISCHERß VOLLBLUT- DENDRITZELLE- IMMUNFUNCTIONTEST
WO2014152048A3 (fr) Ensembles et procédés de réduction de la diaphonie optique dans les systèmes de traitement des particules
ATE221661T1 (de) Zellzählung durch einen immunoassay
BR0308919A (pt) Células-tronco programáveis, desdiferenciadas de origem monocìtica, e sua produção e uso
Mandy et al. Evolution of leukocyte immunophenotyping as influenced by the HIV/AIDS pandemic: A short history of the development of gating strategies for CD4+ T‐cell enumeration
DK1546366T3 (da) Fremgangsmåde til detektion og tælling af mikroorganismer i en pröve
WO2007061881A3 (fr) Systemes et procedes permettant l'analyse biometrique de populations fondatrices de reference
WO2003056330A3 (fr) Systeme de tri de cellules conçu pour trier ou separer des cellules en suspension dans un liquide en ecoulement en fonction de leur grandeur
WO2009131645A3 (fr) Procédés et appareil pour la ségrégation de particules
DK2084508T3 (da) Fremstillingsfremgangsmåde
WO2007006864A3 (fr) Méthode d'évaluation de populations cellulaires
Strauss‐Albee et al. The newborn human NK cell repertoire is phenotypically formed but functionally reduced
Dunay et al. Parallel assessment of Th17 cell frequencies by surface marker co‐expression versus ex vivo IL‐17 production in HIV‐1 infection
EP1684075A3 (fr) Procédé et réactif pour classifier les leucocytes dans le sang animal
WO2005031357A3 (fr) Analyse d'echantillon cellulaire
WO2005059163A3 (fr) Procedes, compositions et trousses pour analyser l'activite enzymatique dans des cellules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase